commercial activity assay, commercial ELISAs and flow cytometry using TF-positive EVs isolated from plasma prepared from untreated and lipopolysaccharide (LPS) treated whole blood from healthy donors. [6] [7] [8] [9] [10] [11] Another disadvantage of antigen assays is that they measure all forms of TF, including degraded TF, and cannot distinguish encrypted versus active TF.
In this tutorial, we will describe our in-house EV TF activity assay.
| PRE-ANALYTICAL SETTINGS
As with other assays, pre-analytical variables can affect the results of the EV TF activity assay. 3, 6 The most important pre-analytical variable is the method used to prepare plasma. Platelet-poor plasma (PPP) is typically prepared by a centrifugation of whole blood at 1500 to 2000 g for 15 minutes at room temperature. Platelet-free plasma (PFP) is prepared by centrifugation of whole blood at 2500 g for 15 minutes at room temperature followed by a second centrifugation at 2500 g for 15 minutes at room temperature as described by the International
Society on Thrombosis and Haemostasis Scientific and Standardization
Committee Collaborative Workshop. 12 Published studies describing the measurement of EV TF activity have used both PPP and PFP. 13 We and others observed a 52%-80% reduction in EV TF activity in PFP compared to PPP. 6,13 Therefore, we would expect more variability and higher EV TF activity using PPP compared with PFP. 
| Preparation of platelet-free plasma
Whole blood is drawn into vacutainers containing 3.2% sodium citrate (Becton Dickinson, Franklin Lakes, NJ, USA). The first 2-3 mL of blood is discarded because it may contain contaminating TF derived from the vessel wall. Vacutainers are gently inverted immediately after blood collection to disperse the anticoagulant. If vacutainers are transported before processing, agitation should be avoided. The time between blood collection and sample processing should be less than 1 hour to avoid activation of monocytes. PFP is prepared by double centrifugation at 2500 g for 15 minutes at room temperature. 12 PFP is aliquoted (110 μL) and frozen by placing at −80°C.
| Preparation of positive and negative controls
Negative control plasma is prepared using whole blood from healthy volunteers immediately after collection. Positive control plasma is prepared from whole blood stimulated with LPS (Sigma Aldrich, MO, USA, 10 μg/mL) for 5 hours at 37°C with agitation. It should be noted that volunteers exhibit a range of responses to LPS.
6,14

| METHODS
We use a two-stage assay to measure TF activity. (1 to <2.0 pg/mL), and strong (>2.0 pg/mL). 13 
| DISCUSSION
The advantages of our EV TF activity assay are its higher sensitivity and specificity compared with antigen assays. The disadvantages of the assays are that it is time consuming, labor intensive and has a high interassay variability. It takes ~4 to 5 hours for a well-trained operator to run the assay. Furthermore, the assay does not separate TF-positive EVs from other TF-positive material in the plasma. In addition, the mean coefficient of variation (CV) for the positive control in seven independent studies was 24% 6 (Y. Hisada and N. Mackman, unpubl. data). Therefore, our in-house EV TF activity assay is too variable for use as a clinical assay.
There are two in-house EV TF activity assays that were developed in parallel. We developed an endpoint assay and the Osanto group developed a kinetic assay. 4, 5 The endpoint assay is presented pg/mL of TF whereas the kinetic assay is presented fM Xa/ min. The two assays gave similar results in 54 plasma samples from pancreatic cancer patients (r = 0.61, P < 0.001). 16 The conversion between the assays can be made using the following equation: y = 0.0009x + 0.0831 where y = pg/mL, x=fM Xa/min). 13 We and others have used the endpoint and kinetic assays EV TF activity assays to show increased levels of EV TF activity are detected in patients with various types of disease, including cancer, endotoxemia, liver injury, cirrhosis, urinary tract infection, and influenza A infection. 13, [17] [18] [19] [20] [21] In cancer, most of the TF-positive EVs appear to be derived from tumors whereas in endotoxemia and other diseases most of the TF-positive EVs are probably derived from activated monocytes. Pancreatic cancer has the highest EV TF activity (16-to 26-fold higher than healthy controls) among different types of cancer. 13 Importantly, increased levels of EV TF activity were associated with venous thromboembolism in patients with pancreatic cancer but not in other types of cancer including brain, colorectal, ovarian, and lung cancer. 13, 16, 22, 23 Interestingly, patients with cirrhosis and acute liver injury have 17-fold and 38-fold increased levels of EV TF activity compared with healthy controls, respectively.
13
Increased levels of EV TF were detected in patients with endotoxemia (nine-fold) and urinary tract infection (six-fold). 13 We recently compared our in-house EV TF activity assay with a commercial EV TF activity assay kit that captures TF-positive EVs onto plates using a non-inhibitory anti-human TF monoclonal antibody (clone: 10H10) (Zymuphen MP-TF, Hyphen BioMed, Neuvillesur-Oise, France). 10 We found that our in-house activity assay had higher sensitivity and specificity, and less background compared with the Zymuphen MP-TF. 10 The higher background of Zymuphen MP-TF may be due to the use of a higher concentration of FVIIa N. Mackman, unpubl. data). Indeed, we observed a 2-to 11-fold increase in sensitivity when we compare our current assay with the new assay. Interestingly, the greatest increases in EV TF activity were observed in samples with lower levels of TF suggesting that we may have reached the upper limit of the assay with samples with higher activity. Another possible improvement may be using magnetic beads to isolate TF-positive EVs from a larger volume of plasma because this can increase sensitivity and specificity, and reduce the time of isolating EVs and washing EVs.
In conclusion, our EV TF activity assays is currently the best way to detect EV TF in plasma. However, we and others are working on new assays that are less time consuming, have increased sensitivity and specificity and have a lower CV. 
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